<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614752</url>
  </required_header>
  <id_info>
    <org_study_id>DWFE_P406</org_study_id>
    <nct_id>NCT05614752</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab</brief_title>
  <official_title>A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study is a large-scale, prospective, and multi-institutional observational&#xD;
      study.&#xD;
&#xD;
      Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study&#xD;
      period before and after administration of Pexuclue tablet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected based on patient's medical records from daily visit. Enrolled subjects&#xD;
      will take a Patient Reported Outcome (PRO) survey including Quality of life evaluation&#xD;
      (GERD-HRQL) and self-awareness symptom (RDQ).&#xD;
&#xD;
      The survey will be done twice (before and after the administration of Fexuclue tablet)&#xD;
      electronically through an application (e-PRO).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Average score change in RdQ</measure>
    <time_frame>At least 2 weeks (up to 8 weeks) compared to baseline</time_frame>
    <description>choosing from given option (none, very slight, slight, medium, severe, very severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average score change in GERD-HRQL</measure>
    <time_frame>At least 2 weeks (up to 8 weeks) compared to baseline</time_frame>
    <description>scale from 1 to 5, higher the score, low quality of life</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <description>treated with Fexuclue Tablet 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexuprazan</intervention_name>
    <description>Fexuclue Tablet 40mg</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population was calculated by the average of changes and standard deviation at two&#xD;
        weeks and by referring to Michael Shaw et al. (2008)'s RDQ score (reverse flow, heartburn,&#xD;
        indigestion)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult aged 19 years to 75 years (on registration date)&#xD;
&#xD;
          2. Patient scheduled to administer Fexuclue tablet based on the medical judgment of&#xD;
             investigator.&#xD;
&#xD;
          3. Patient who agreed to participate in this observation study and signed Informed&#xD;
             Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A person who falls under the prohibition of administration according to the permission&#xD;
             for Fexuclue Tablet&#xD;
&#xD;
               -  Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue&#xD;
                  tablet and a history thereof&#xD;
&#xD;
               -  Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations&#xD;
&#xD;
               -  Pregnant and lactating women&#xD;
&#xD;
               -  Patients with genetic problems such as galactose intolerance, Lapp lactase&#xD;
                  deficiency, or glucose-galactose malabortion&#xD;
&#xD;
          2. A person who participates in another clinical trial and is administering (applying)&#xD;
             clinical trial drugs or clinical trial medical devices;&#xD;
&#xD;
          3. In addition to the above, a person who has determined that the researcher (the doctor&#xD;
             in charge) is not suitable for participation in this observation study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seungyoung Seo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohee Kim</last_name>
    <phone>02-550-8665</phone>
    <email>2210325@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jeonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seungyoung Seo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not yet decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

